MedTrace Logo

A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors

NCT05765851 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 78

Last updated 2025-05-11

No results posted yet for this study

Summary

This study will evaluate the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors.

Conditions

Interventions

DRUG

DS-1103a

One IV infusion Q3W on Day 1 of each 21-day cycle

DRUG

T-DXd

One IV infusion Q3W on Day 1 of each 21-day cycle

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-30
Primary Completion
2026-06-30
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States
  • Canada
  • France
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05765851 on ClinicalTrials.gov